Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Galapagos quits cell therapy. Europe’s CGT reckoning begins.

Galapagos quits cell therapy. Europe’s CGT reckoning begins.

Late on Monday night in California — 10:30 p.m. PT

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

When Dr. Peter Marks walked out of the FDA’s headquarters

The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here

The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here

From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care

From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care

A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong

A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong

A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see

A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see

The explainable aging clock regulators might actually like

The explainable aging clock regulators might actually like

MOST POPULAR

News

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Dermatology’s next play: bispecifics that shut down OX40L and TNF
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top